Clinical Trials Logo

Filter by:
NCT ID: NCT06182852 Not yet recruiting - Diabete Type 2 Clinical Trials

The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus

Start date: January 1, 2024
Phase:
Study type: Observational

Through an one-year follow-up, to explore the effect of GLP-1 receptor agonist on bone metabolism in patients with diabetes.

NCT ID: NCT06182735 Recruiting - Clinical trials for Renal Cell Carcinoma

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, single-arm study conducted to evaluate the safety, tolerability, PK, and preliminary efficacy of CGC729 with Relapsed or Metastatic advanced renal cell carcinoma. Condition or disease:Renal Cell Carcinoma Intervention/treatment: Biological: CD70 CAR-NKT cells Phase 1

NCT ID: NCT06182722 Recruiting - Depressive Disorder Clinical Trials

Association of Peripheral Immune Cells With Antidepressant Treatment Response

Start date: March 13, 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational study is discovering potential biomarkers to predict antidepressant treatment response in patients with major depressive disorder (MDD) while comparing the transcriptomic changes between patients with MDD and healthy controls as well as before and after antidepressant treatment. Eligible patients will be assessed at Week 1, Week 2, Week 4 and Week 8 while healthy normal volunteers will only be evaluated at baseline. Assessments will include the following: an interview about mental and physical health, a physical examination including drawing of venous blood samples and several psychiatric rating scales.

NCT ID: NCT06182696 Recruiting - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Start date: October 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM

NCT ID: NCT06182657 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to explore the prognostic value of pathological remission after one cycle of induction chemotherapy in locally advanced nasopharyngeal carcinoma, and the change of immune micro-environment after one cycle induction chemotherapy, including the density of immune cells infiltration and tertiary lymphoid structures.

NCT ID: NCT06182644 Recruiting - Colorectal Cancer Clinical Trials

Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors

FAPI
Start date: January 11, 2024
Phase: N/A
Study type: Interventional

The latest research has found that the use of positron-labeled FAP inhibitors for targeting FAP has achieved very good results in displaying tumor stroma, especially for tumors with poor FDG PET/CT observation, such as liver cancer, renal cancer, and gastric cancer. Although the studies were based on small sample data or case reports, they achieved significantly better results than 18F-FDG [13,15-17]. For patients who meet the inclusion and exclusion criteria, using FAPI PET/CT and FDG PET/CT imaging may have guiding significance for your treatment. If distant metastasis is found, information such as the location, size, and quantity of metastasis can be provided to provide objective imaging information for further treatment; We will promptly provide detailed information to you and your supervising physician, who will guide your personalized treatment. The drugs used have undergone strict quality inspection, and currently, no adverse reactions have been found in multiple medical institutions both domestically and internationally. If you experience any discomfort, new changes in your condition, or any unexpected circumstances during the study period, regardless of whether it is related to the study or not, you should promptly notify your doctor or contact our research leader. He/she will make a judgment and provide appropriate medical treatment. We will provide a certain proportion of compensation for any additional visits and expenses incurred during this examination. The entire research process is under the supervision of relevant departments of Guangdong Provincial People's Hospital. If you encounter any questions during the research process, you can consult the research doctor.

NCT ID: NCT06182618 Recruiting - Metabolic Syndrome Clinical Trials

Retrospective Analysis for Patients With Metabolic Syndrome

Start date: June 1, 2023
Phase:
Study type: Observational

The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

NCT ID: NCT06182592 Not yet recruiting - Clinical trials for High-risk (Secondary) Acute Myeloid Leukemia

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

Start date: January 2024
Phase: Phase 3
Study type: Interventional

The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.

NCT ID: NCT06182488 Recruiting - Acute Abdomen Clinical Trials

Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Emergency Laparotomy

ERAS
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the safety and effectiveness of the ERAS protocols compared to a conventional care protocols in patients who received emergency laparotomy. The main question it aims to answer are: • Can the ERAS protocols be used safely and effectively in patients undergoing emergency laparotomy? Participants will be randomised into the ERAS group and the conventional group and will be given the ERAS protocols and the conventional protocols in the perioperative period. Researchers will compare the ERAS group with the conventional group to see if the ERAS programme is effective.

NCT ID: NCT06182384 Completed - Clinical trials for Moderate-to-Severe Plaque Psoriasis

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Start date: December 24, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of SHR-1314 injection in healthy subjects at different specifications devices.